Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma

BACKGROUND: Approximately 40% patients of diffuse large B‐cell lymphoma (DLBCL) would develop disease recurrence/progression after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to prolong...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoyan, Yu, Lu, Jiang, Xinlu, Ding, Kaiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225180/
https://www.ncbi.nlm.nih.gov/pubmed/36912128
http://dx.doi.org/10.1002/cam4.5790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225180/
https://www.ncbi.nlm.nih.gov/pubmed/36912128
http://dx.doi.org/10.1002/cam4.5790

Ejemplares similares